Zalevsky Jonathan 4

What Happened

• Jonathan Zalevsky, Chief Research & Development Officer at Nektar Therapeutics (NKTR), sold 5,681 shares on June 30, 2026. The shares were sold at $70.00 each for a total proceeds of $397,670. This was a sale (S), not a purchase.

Key Details

• Transaction date and price: June 30, 2026 — 5,681 shares sold at $70.00 per share.
• Total value: $397,670.
• Shares owned after transaction: Not provided in the supplied summary (see the full Form 4 for post-transaction beneficial ownership).
• Filing date / timeliness: Form filed July 2, 2026; no late filing indicated in the provided data.
• Footnote: The sale was made under a pre-established Rule 10b5-1 trading plan adopted by Mr. Zalevsky on March 13, 2026 (per Form 4 footnote). 10b5-1 plans allow insiders to execute trades according to a preset schedule or formula.

Context

• This was an ordinary-course sale under a 10b5-1 plan. Such pre-arranged plans are commonly used to avoid trading on material nonpublic information; they do not, by themselves, indicate the insider’s current view of the company. The transaction code S denotes a sale of shares.